ORGO
Organogenesis Holdings Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.71
+4.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−80.5x
Market Cap
$220.03M
MomentumView details →
1D Return
+4.27%
YTD Return
−67.14%
RSI (14)
38.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−80.5x
Market Cap
$220.03M
RSI (14)
38.0
MomentumView details →
1D Return
+4.27%
YTD Return
−67.14%
SummaryUpdated Jun 1, 2026
Organogenesis Holdings Inc. (NASDAQ:ORGO) is a regenerative medicine company founded in 1985 and headquartered in Canton, Massachusetts. The company develops, manufactures, and commercializes advanced biological solutions primarily for wound care and surgical applications. Since going public in 2017, Organogenesis has established itself as a leading player in the regenerative medicine space, focusing on products that harness the body's natural healing processes to treat complex medical conditions.
Similar companies
Latest newsMore news →